Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors
12 Diciembre 2014 - 6:30AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company
focused on the discovery, development and commercialization of
novel protein therapeutics for cancer and rare diseases, today
announced the appointment of Francois Nader, M.D., M.B.A, to its
Board of Directors.
“Dr. Nader brings an experienced executive’s knowledge of drug
development and commercialization in the rare disease area to our
board, and we look forward to his contributions to the company’s
future,” said John Knopf, Ph.D., Chief Executive Officer of
Acceleron.
Dr. Nader has been President, Chief Executive Officer and a
member of the Board of Directors of NPS Pharma since 2008. During
his tenure, Dr. Nader transformed NPS Pharma into a leading global
rare disease company. Dr. Nader is a 30-year veteran of the
healthcare industry. He joined NPS Pharma in 2006 as chief medical
and commercial officer and was promoted to chief operating officer
in 2007. Previously, he was a venture partner at Care Capital. Dr.
Nader served on the North America Leadership Team of Aventis and
its predecessor companies and held a number of executive positions
including senior vice-president, integrated healthcare markets and
North America medical and regulatory affairs. Prior to that, Dr.
Nader led the global commercial operations at the Pasteur Vaccines
division of Rhone-Poulenc. Dr. Nader currently serves as chairman
of the Board of Trustees for BioNJ, New Jersey’s trade organization
representing the biotechnology industry. He is also a Board member
of the Biotechnology Industry Organization (BIO), the New Jersey
Chamber of Commerce, Trevena, Inc. and Clementia Pharmaceuticals.
Dr. Nader earned his French Doctorate in Medicine from St. Joseph
University (Lebanon) and his Physician Executive MBA from the
University of Tennessee.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
protein therapeutics for cancer and rare diseases. The company is a
leader in understanding the biology of the Transforming Growth
Factor-Beta (TGF-β) protein superfamily, a large and diverse group
of molecules that are key regulators in the growth and repair of
tissues throughout the human body, and in targeting these pathways
to develop important new medicines. Acceleron has built a highly
productive R&D platform that has generated innovative clinical
and preclinical protein therapeutic candidates with novel
mechanisms of action. These protein therapeutic candidates have the
potential to significantly improve clinical outcomes for patients
with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.
Acceleron Pharma Inc.Kevin F. McLaughlin, 617-649-9204Senior
Vice President and Chief Financial OfficerorMedia contact:Suda
Communications LLCMaureen L. Suda, 585-387-9248
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Acceleron Pharma Inc (NASDAQ): 0 recent articles
Más de Acceleron Pharma Inc. (MM) Artículos de Noticias